Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | YARS1 | P54577 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19426105 | 0.84 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL19426175 | 0.81 | FFAR2 (0.34) | ADRA2AADRA2BADRA2CADRA1AYARS1 | |
| SCHEMBL19426172 | 0.74 | ADRA2A (0.46) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL19426173 | 0.70 | ADRB1 (0.43) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL15631302 | 0.68 | ADRA1A (0.57) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL19426178 | 0.68 | ADRB2 (0.49) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL27472717 | 0.66 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL15495182 | 0.66 | GAA (0.48) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL29852847 | 0.66 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRB2 | |
| SCHEMBL9768011 | 0.66 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | ADRA2A 2852/4885ADRA2B 3350/4885ADRA2C 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.